Business context and reporting period
The supplied filing is Transgenomic, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2014, not a filing identified as Precipio, Inc. The company operated Laboratory Services and Genetic Assays and Platforms businesses focused on genetic testing, molecular diagnostics, instruments, and related consumables.
Unless otherwise noted, financial amounts below are in U.S. dollars. The filing states share and per-share figures reflect a 1-for-12 reverse stock split effective January 27, 2014.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Net sales | $6.251 million | $7.374 million; down 15% |
| Gross profit / margin | $2.494 million / 40% | $3.255 million / 44% |
| Operating loss | $3.539 million | $3.820 million |
| Net loss | $4.176 million | $3.586 million |
| Net loss available to common stockholders | $4.406 million | $3.767 million |
| Loss per common share | $0.60 | $0.54 |
| Cash used in operating activities | $3.866 million | $3.334 million |
Revenue declined in both segments: Laboratory Services fell 17% to $3.688 million, and Genetic Assays and Platforms fell 13% to $2.563 million. The company attributed the Laboratory Services comparison partly to unusually high first-quarter 2013 Nuclear Mitome testing as it worked through a prior-year backlog; instrument sales were lower in the other segment.
SG&A was $5.288 million, down from $6.311 million, primarily reflecting lower bad-debt provision and reduced sales-force costs following a channel-strategy change. R&D was $0.745 million, versus $0.764 million. Interest expense was $0.182 million. Income tax expense was $0.505 million, including approximately $0.5 million of deferred tax expense associated with tax amortization of goodwill; $0.4 million related to prior periods.
At March 31, 2014, cash was $1.743 million; current assets were $12.680 million and current liabilities $8.046 million, yielding working capital of $4.634 million. Total assets were $30.717 million. Total debt was $3.758 million, compared with $6.560 million at year-end 2013; the revolver was fully paid down and the remaining term loan was $3.758 million. The company reported $14.292 million of stockholders’ equity.
Cash declined by $3.866 million from operations and $0.093 million from investing, offset by $4.071 million of financing cash flow; ending cash increased $0.117 million to $1.743 million. Financing included $6.970 million of Series B preferred stock proceeds, substantially offset by debt repayments.
Material changes, outlook, and risks
- On March 5, the company issued 1,443,297 shares of Series B convertible preferred stock to affiliates of Third Security, LLC for approximately $7.0 million. The shares were initially convertible one-for-one into common stock, subject to adjustment. The financing also triggered repricing and additional issuance of certain warrants.
- A March 3 loan amendment suspended term-loan principal and interest payments from March 1, 2014 through March 31, 2015; payments were scheduled to resume April 1, 2015. The loan is secured by company assets and includes financial covenants and a subjective acceleration provision. The company said it was compliant with financial covenants at quarter-end.
- Management stated that existing liquidity was expected to fund operations for at least 12 months, while acknowledging uncertainty about revenue growth, cost reductions, and access to additional capital. No quantified revenue or earnings guidance was provided.
- Management highlighted ICE COLD-PCR as a strategic technology for sensitive mutation detection and potential liquid-biopsy applications, and cited a newly issued patent protecting the technology until 2031. These are prospective opportunities, not reported commercial results.
- Key disclosed risks include ongoing operating losses and cash use, lower reimbursement rates from government and private payors, demand and long sales cycles for instruments, competition, and foreign-exchange exposure. The company wrote off approximately $1.0 million of prior-period receivables during the quarter and recorded a $0.673 million doubtful-account provision.
- Management reported no material changes to previously disclosed risk factors, no material subsequent events, and no off-balance-sheet arrangements. It stated disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- Confirm the issuer identity: this source is a Transgenomic, Inc. filing, despite the request metadata naming Precipio, Inc.
- Review the Series B conversion, dividend, and adjustment provisions, related-party terms, and potential dilution from preferred stock, warrants, and other securities.
- Assess cash runway against the reported $3.866 million quarterly operating cash outflow, the company’s liquidity assumptions, and the term-loan payment restart in April 2015.
- Track revenue trends, margins, receivable collections and write-offs, and reimbursement rates, particularly in Laboratory Services.
- Evaluate whether ICE COLD-PCR partnerships, tests, and commercialization generate measurable revenue, and review the associated intellectual-property rights and execution risks.